checkAd

     133  0 Kommentare Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)

    Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic Encephalopathy is caused by cirrhosis of the liverAs complications from chronic liver disease increase, recognizing OHE is …

    • Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults
    • Overt Hepatic Encephalopathy is caused by cirrhosis of the liver
    • As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with their healthcare providers to find the right management plan for them

    LAVAL, QC / ACCESSWIRE / May 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced award-winning actor, Bellamy Young, as the brand ambassador in a new campaign to raise awareness of Xifaxan, the first and only FDA approved medication to reduce the risk of overt hepatic encephalopathy (OHE) recurrence in adults. Overt hepatic encephalopathy is a complication of cirrhosis that can happen when the liver cannot filter toxins from the blood, and the toxins build up and reach the brain. It is projected that as many as four out of five people with cirrhosis may eventually develop some form of HE.

    "When I first started talking about OHE, the most common response I received from people was ‘I wish I knew', a sentiment that echoed my experience when my father was diagnosed with OHE. We didn't know the symptoms of OHE could persist or that it could worsen over time. But when my dad had OHE we also didn't know as much as we do today, and we didn't have the same management options," said Bellamy Young, whose father suffered from OHE when she was in high school. "I want to help today's patients and caregivers to know more than my family did with my father, and I encourage them to talk to their health care providers about managing the risk of OHE recurrence. I hope people will go to Xifaxan.com to know more."

    Lesen Sie auch

    To kick off the new Xifaxan marketing campaign, Bellamy is sharing her personal OHE story on www.Xifaxan.com/ohe/ and is in a multi-channel advertising campaign that will be seen across digital mediums, including a 60-second TV spot. Bellamy will also be engaging with HCPs, caregivers, and patients to exchange learnings about OHE by chronicling these experiences and sharing insights on her social media handles throughout the year to support others in knowing more about OHE so they can make informed decisions about disease management. As an ambassador, she will be encouraging caregivers to take an active role as a health advocate for their loved ones.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin) Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic Encephalopathy is caused by cirrhosis of the liverAs complications from chronic liver disease increase, recognizing OHE is …